Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 14, 2015; 21(18): 5568-5574
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5568
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5568
Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication
Jae Jin Hwang, Dong Ho Lee, Ae-Ra Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, South Korea
Author contributions: Hwang JJ and Lee DH were responsible for the study conception and design, data analysis and interpretation, and manuscript drafting; Lee AR, Yoon H, Shin CM, Park YS and Kim N critically revised the article for important intellectual content; all the authors reviewed and approved the final version to be published.
Ethics approval: The study was reviewed and approved by the Seoul National University Bundang Hospital Institutional Review Board.
Conflict-of-interest: No potential conflicts of interest relevant to this article were reported.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dong Ho Lee, MD, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam, Gyeonggi-do 463-707, South Korea. dhljohn@yahoo.co.kr
Telephone: +82-31-7877006 Fax: +82-31-7874051
Received: November 19, 2014
Peer-review started: November 19, 2014
First decision: December 11, 2014
Revised: January 2, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: May 14, 2015
Processing time: 180 Days and 10.3 Hours
Peer-review started: November 19, 2014
First decision: December 11, 2014
Revised: January 2, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: May 14, 2015
Processing time: 180 Days and 10.3 Hours
Core Tip
Core tip: This study aimed to evaluate the efficacy of the 14-d moxifloxacin-based triple therapy compared to the corresponding 7-d regimen for second-line Helicobacter pylori (H. pylori) eradication in South Korea. The H. pylori-eradication rates in the RAM-14 group were significantly higher compared to the RAM-7 group for both the intention-to-treat and per-protocol analysis. The high eradication rate, excellent compliance, and safety of the 14-d regimen suggest its potential suitability as an alternative to the standard bismuth-based quadruple therapy. The 14-d moxifloxacin-based triple therapy is a significantly more effective second-line eradication treatment than the 7-d alternative for H. pylori infection in Korean patients.